000 01026 a2200289 4500
005 20250516042150.0
264 0 _c20120322
008 201203s 0 0 eng d
022 _a1029-2403
024 7 _a10.3109/10428194.2011.580027
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aJoerger, Markus
245 0 0 _aHigh-dose methotrexate in patients with primary central nervous system lymphoma: does drug exposure really matter?
_h[electronic resource]
260 _bLeukemia & lymphoma
_cOct 2011
300 _a1825-7 p.
_bdigital
500 _aPublication Type: Journal Article; Comment
650 0 4 _aCentral Nervous System Neoplasms
_xpathology
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aMale
650 0 4 _aMethotrexate
_xpharmacokinetics
700 1 _aHuitema, A D R
700 1 _aIllerhaus, G
700 1 _aFerreri, A J M
773 0 _tLeukemia & lymphoma
_gvol. 52
_gno. 10
_gp. 1825-7
856 4 0 _uhttps://doi.org/10.3109/10428194.2011.580027
_zAvailable from publisher's website
999 _c20914148
_d20914148